WESPAC Advisors SoCal LLC Has $1.44 Million Stake in Eli Lilly and Company (NYSE:LLY)

WESPAC Advisors SoCal LLC lowered its stake in shares of Eli Lilly and Company (NYSE:LLY) by 88.8% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,860 shares of the company’s stock after selling 14,816 shares during the period. WESPAC Advisors SoCal LLC’s holdings in Eli Lilly and Company were worth $1,436,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently made changes to their positions in the company. Rockline Wealth Management LLC increased its position in Eli Lilly and Company by 5.1% in the 4th quarter. Rockline Wealth Management LLC now owns 3,097 shares of the company’s stock valued at $2,391,000 after buying an additional 150 shares in the last quarter. Tempus Wealth Planning LLC grew its stake in Eli Lilly and Company by 14.9% in the fourth quarter. Tempus Wealth Planning LLC now owns 2,750 shares of the company’s stock valued at $2,123,000 after acquiring an additional 356 shares during the period. First Dallas Securities Inc. increased its holdings in shares of Eli Lilly and Company by 2.6% during the fourth quarter. First Dallas Securities Inc. now owns 4,012 shares of the company’s stock valued at $3,097,000 after acquiring an additional 100 shares in the last quarter. Calamos Wealth Management LLC raised its holdings in Eli Lilly and Company by 1.1% during the fourth quarter. Calamos Wealth Management LLC now owns 28,284 shares of the company’s stock worth $21,835,000 after buying an additional 319 shares during the last quarter. Finally, Calamos Advisors LLC lifted its position in Eli Lilly and Company by 1.2% in the 4th quarter. Calamos Advisors LLC now owns 291,976 shares of the company’s stock valued at $225,405,000 after acquiring an additional 3,433 shares in the last quarter. Institutional investors and hedge funds own 82.53% of the company’s stock.

Analyst Ratings Changes

LLY has been the subject of a number of recent research reports. StockNews.com lowered Eli Lilly and Company from a “buy” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein began coverage on Eli Lilly and Company in a research report on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 price target for the company. Wolfe Research began coverage on shares of Eli Lilly and Company in a research report on Friday, November 15th. They set an “outperform” rating and a $1,000.00 price target on the stock. Citigroup reduced their price objective on shares of Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research report on Tuesday, January 28th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on Eli Lilly and Company from $1,025.00 to $1,015.00 and set a “buy” rating on the stock in a research note on Monday, November 4th. Five analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $997.50.

Eli Lilly and Company Trading Up 2.1 %

Shares of LLY opened at $843.82 on Thursday. Eli Lilly and Company has a fifty-two week low of $691.10 and a fifty-two week high of $972.53. The business has a 50-day moving average of $785.46 and a 200 day moving average of $843.28. The firm has a market cap of $801.05 billion, a P/E ratio of 91.22, a price-to-earnings-growth ratio of 1.72 and a beta of 0.42. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.97 and a current ratio of 1.27.

Eli Lilly and Company Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be paid a $1.50 dividend. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.30. The ex-dividend date is Friday, February 14th. This represents a $6.00 annualized dividend and a dividend yield of 0.71%. Eli Lilly and Company’s dividend payout ratio (DPR) is presently 64.86%.

Eli Lilly and Company announced that its board has initiated a share repurchase plan on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to repurchase up to 2% of its stock through open market purchases. Stock buyback plans are generally an indication that the company’s board believes its stock is undervalued.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total value of $723,042.00. Following the completion of the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.13% of the company’s stock.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.